Free Trial
→ Market down? Do this now. (From Colonial Metals) (Ad)

Cerus Q2 2023 Earnings Report

Cerus logo
$1.65 -0.09 (-5.17%)
As of 02/21/2025 04:00 PM Eastern
Earnings HistoryForecast

Cerus EPS Results

Actual EPS
-$0.07
Consensus EPS
-$0.05
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Cerus Revenue Results

Actual Revenue
$38.85 million
Expected Revenue
$40.80 million
Beat/Miss
Missed by -$1.95 million
YoY Revenue Growth
N/A

Cerus Announcement Details

Quarter
Q2 2023
Date
8/2/2023
Time
N/A

Conference Call Resources

Conference Call Audio

Powered by Quartr

Cerus Earnings Headlines

Cerus Corporation’s 2024 Earnings Call Highlights Growth and Expansion
February 21 at 8:20 PM | tipranks.com
Cerus Corporation Announces Full-Year and Fourth Quarter 2024 Financial Results
February 21 at 8:13 PM | businesswire.com
The FED is losing the war on inflation
It's no longer just a “guesstimate” – Inflation is indeed getting worse. And although we want to believe the Fed has a good grip on it, they don't. Right now, the suits over there are caught between a rock and a hard place. Either they watch as inflation grows, or they tear it down and send us into a full-blown recession. The kicker here is that neither of these are good for you. Whichever pill we end up with, prices will still climb higher as the value of the dollar sinks lower. The only real way out for the regular person is to increase your earning power. By increasing your income to match prices as they flare up… You’ll stay ahead of the impending doom we're running face-first into. And if you're looking for a strategy to help increase your income in 2025… I've got just the thing for you! You see, last year, I was able to grow a $10k model account to a little over $63k with 100 trade alerts But I changed my trading rules and more than doubled my results on those 100 published trades. I'm now calling them Warped Options…
February 22, 2025 | WealthPress (Ad)
Cerus (CERS) Receives a Buy from Cantor Fitzgerald
February 21 at 8:13 PM | markets.businessinsider.com
Cerus targets 8%-11% revenue growth for 2025 with strong IFC demand and global expansion
February 21 at 4:29 AM | msn.com
Cerus reports Q4 EPS (1c), consensus (1c)
February 21 at 4:29 AM | markets.businessinsider.com
See More Cerus Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Cerus? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Cerus and other key companies, straight to your email.

About Cerus

Cerus (NASDAQ:CERS) operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. Cerus Corporation was incorporated in 1991 and is headquartered in Concord, California.

View Cerus Profile

More Earnings Resources from MarketBeat

Earnings Tools
Earnings By Country
Latest Articles